Target intelligence / Profile preview

S100 calcium-binding protein A8 (S100A8)

Target
S100A8
Molecular classification
Calcium-binding protein (EF-hand family), S100 protein family, Alarmin (DAMP, damage-associated molecular pattern), Other
01

Overview

S100 calcium-binding protein A8 (S100A8) is a member of the S100 family of EF-hand calcium-binding proteins predominantly expressed in neutrophils and monocytes. It functions both intra- and extracellularly, mainly as a regulator and effector in inflammation and innate immune responses. S100A8 forms heterodimers (and higher-order complexes) with S100A9 (calprotectin), which are critical for chemotaxis, cytoskeletal reorganization, regulation of NADPH oxidase, and ROS production, as well as modulation of inflammatory signaling via receptors such as RAGE and TLR4. Its expression is elevated in a range of inflammatory and infectious diseases and certain cancers, and it serves as a biomarker for disease activity in several immune-mediated conditions. Structural studies show that it binds both calcium and zinc, which regulate its oligomerization and function[1][2][4][5][6][7].

Other names
Protein S100-A8Calgranulin AMRP8p8Cystic fibrosis antigenLeukocyte L1 complex light chainMigration inhibitory factor-related protein 8Calprotectin L1L subunitUrinary stone protein band ACAGACFAGCGLACP-10L1AgMA387MIFNIF60B8AG
02

Mechanism of action

Immune modulation; Inhibition of S100A8/A9–receptor interactions (e.g., TLR4, RAGE) to reduce inflammatory signaling[2][5]; Modulation of myeloid cell activity and migration

03

Biological functions

Immune responseRegulation of inflammationChemotaxis and cell migrationCytoskeleton modulationRegulation of ROS (reactive oxygen species) productionModulation of NADPH oxidaseSignal transductionOther
04

Disease associations

InflammationCancerInfectionAutoimmune diseaseCardiovascular diseaseNeurodegenerative diseaseCystic fibrosisOther
05

Safety considerations

Targeting S100A8 may have immunosuppressive effects, potentially increasing infection riskMay disrupt normal neutrophil and macrophage functionPotential off-target effects due to wide tissue distribution and involvement in innate immune regulation[2]
06

Interacting drugs

No specific approved drugs directly target S100A8 in clinical use; investigational agents (e.g., Tasquinimod, paquinimod) modulate S100A8/A9 activity[2].
07

Biomarkers

Calprotectin (S100A8/A9 complex) levels in blood, serum, or stool as a biomarker for inflammation, disease activity in inflammatory bowel disease and other autoimmune/inflammatory disorders[2][5]S100A8 as a prognostic biomarker in cancer and infection

Beyond the preview

Go deeper on S100 calcium-binding protein A8 (S100A8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on S100 calcium-binding protein A8 (S100A8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call